Dupixent Positive EoE Phase 3 Data
Key Questions
What positive results did Dupixent show in EoE clinical trials?
Sanofi and Regeneron's Dupixent demonstrated significant esophageal distensibility gains and structural improvements in eosinophilic esophagitis from Phase 3 data. New Phase 4 findings reinforce these outcomes and support broader use in immunology indications.
How did real-world Dupixent data perform for eczema in Canada?
Positive real-world results from Canada highlight Dupixent's effectiveness as a leading biologic for eczema patients. These findings bolster Regeneron and Sanofi's position following recent pediatric approvals.
What were Sanofi's Q1 sales figures and growth?
Dupixent contributed to Q1 sales of €4.2 billion, reflecting 31% year-over-year growth. Overall company sales rose amid new launches and strategic acquisitions.
What is the updated fair value estimate for Sanofi shares?
Analysts have set a fair value of €95.53 for Sanofi, implying about 30% upside from recent levels around €73.06. This reflects strong immunology momentum and Q1 performance.
Who is Sanofi's new CEO and what is the focus?
Sanofi appointed Belén Garijo as Chief Executive Officer to accelerate strategic execution and strengthen R&D innovation. The leadership transition coincides with higher sales and pipeline advancements.
Sanofi/Regeneron DUPIXENT shows significant esophageal distensibility gains and structural improvements in EoE. New Ph4 data, real-world Canada eczema results, and Q1 sales €4.2B +31% bolster €95.53 fair value (+30% vs €73.06), reinforcing immunology momentum post-peds approvals and Q1 beat.